arrow
T

Thomas J. George

university of florida
H指数:55
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial

淋巴结靶向、mKRAS特异性的两亲性疫苗在胰腺癌中的研究:AMPLIFY-7P随机II期试验

2026-10-230
OAAI
Phase 1/2 study of INCAGN01876, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, plus immunotherapy for advanced cancers

INCAGN01876(一种抗糖皮质激素诱导的肿瘤坏死因子受体激动剂单克隆抗体)联合免疫疗法治疗晚期癌症的Ⅰ/Ⅱ期研究

2026-07-300
OAAI
Neoadjuvant Therapy for Localized Pancreatic Cancer

局部胰腺癌的新辅助治疗

Cancers
IF4.4
2026-04-030
OAAI
NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with “quadruple wild-type” (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated

NSABP FC-11:一项基于HER2状态(扩增、非扩增[野生型]或突变)的尼拉替尼联合曲妥珠单抗或尼拉替尼联合西妥昔单抗治疗“四重野生型”(KRAS/NRAS/BRAF/PIK3CA)转移性结直肠癌的II期研究

2025-08-090
PRE
Utilizing Patient Input in Rectal Cancer Trial Design

利用患者反馈进行直肠癌试验设计

2025-03-190
PRE
Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis

肿瘤和淋巴结分期对III期结直肠癌患者辅助奥沙利铂为基础化疗疗效的影响:一项ACCENT合并分析

2025-03-010
OAAI
Impact of RAS and BRAFV600E mutations on tumor immune microenvironment and associated genomic alterations in patients with microsatellite instability (MSI) or DNA mismatch repair deficient (dMMR) colorectal cancers

RAS和 BRAFV600E 突变对微卫星不稳定(MSI)或DNA错配修复缺陷(dMMR)结直肠癌患者肿瘤免疫微环境及相关基因组改变的影响

2024-09-011
PRE